Quotient Diagnostics Ltd.
This article was originally published in Start Up
Executive Summary
Quotient Diagnostics is among the latest group of contenders betting that its diagnostic system can displace existing ones and grow the market for point-of-care diabetes testing. The firm is pinning its hopes not only on a new sort of chemical-binding technology, but more importantly on the incorporation of that science into a diagnostic system that the company claims is simpler, lighter, and smaller than competing point-of-care offerings.
You may also be interested in...
Start-Up Previews (10/20080
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Making Inroads in Predictive Toxicology," features profiles of Cellumen, GliaGen, Horizon Discovery and SimuGen. Plus these Start-Ups Across Health Care: Acacia Pharma, InspireMD, MicroTransponder and Quotient Diagnostics.
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.